Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Coherus BioSciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-193.4 Mil. Coherus BioSciences's Total Assets for the quarter that ended in Dec. 2023 was $629.6 Mil.
Therefore, Coherus BioSciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.31.
The historical rank and industry rank for Coherus BioSciences's Equity-to-Asset or its related term are showing as below:
CHRS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39 Med: 0.13 Max: 0.36
Current: -0.31
During the past 12 years, the highest Equity to Asset Ratio of Coherus BioSciences was 0.36. The lowest was -0.39. And the median was 0.13.
CHRS's Equity-to-Asset is ranked worse than 87.6% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs CHRS: -0.31
Coherus BioSciences Equity-to-Asset Historical Data
The historical data trend for Coherus BioSciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Coherus BioSciences's Equity-to-Asset
For the Biotechnology subindustry, Coherus BioSciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus BioSciences's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's Equity-to-Asset falls into.
Coherus BioSciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Coherus BioSciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Coherus BioSciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Coherus BioSciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Coherus BioSciences (Coherus BioSciences) Business Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your 